Diffuse panbronchiolitis

European Respiratory Journal

Volumn 28, Issue 4, 2006, Pages 862-871

  Poletti, V ^a,b   Casoni, G ^a   Chilosi, M ^d   Zompatori, M ^c  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

Diffuse panbronchiolitis; Erythromycin; Foamy macrophages; Human leukocyte antigen haplotype; Macrolides

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BRONCHODILATING AGENT; CLARITHROMYCIN; ERYTHROMYCIN; GLUCOCORTICOID; INTERLEUKIN 8; JOSAMYCIN; MACROLIDE; MACROPHAGE INFLAMMATORY PROTEIN 1; MUCOLYTIC AGENT; OXYGEN; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATION; BARE LYMPHOCYTE SYNDROME; BRONCHIECTASIS; BRONCHIOLITIS; CD8+ T LYMPHOCYTE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY FAILURE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DEATH; DIFFERENTIAL DIAGNOSIS; DIFFUSE PANBRONCHIOLITIS; EVIDENCE BASED MEDICINE; GENETIC PREDISPOSITION; HAEMOPHILUS INFLUENZAE; HISTOPATHOLOGY; HUMAN; IMMUNOREGULATION; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; LUNG FUNCTION TEST; LYMPHOCYTIC INFILTRATION; MICROBIOLOGICAL EXAMINATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXYGEN THERAPY; PATHOGENESIS; PATHOLOGICAL ANATOMY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; SINUSITIS; SPUTUM CULTURE; THORAX RADIOGRAPHY; INTERSTITIAL LUNG DISEASE; LUNG; PATHOLOGY; RADIOGRAPHY; REVIEW;

ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MACROLIDES; RESPIRATORY FUNCTION TESTS;

EID: 33847339726     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00131805     Document Type: Article

References (93)

1. Homma H, Yamanaka A, Tanimoto S, et al. Diffuse I panbronchiolitis: a disease of the transitional zone of the lung. Chest 1983; 83: 63-69.
2. Iwata M, Sato A, Colby TV. Diffuse panbronchiolitis. In:, Epler GR, ed. Diseases of the bronchioles. New York, Raven Press, 1994; pp. 153-179.
3. Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis. Naika 1969; 23: 442-451.
4. Sugiyama Y. Diffuse panbronchiolitis. Clin Chest Med 1993. 14: 765-772.
5. Tsang KWT. Diffuse panbronchiolits: diagnosis and treatment. Clin Pulm Med 2000; 7: 245-252.
6. Homma H. Diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1975; 13: 383-395.
7. Izumi T, Doi O, Nobechi A, et al. Nation-wide survey of diffuse panbronchiolitis. Annual Report on the study of interstitial lung disease in 1982. Grant-in Aid from the Ministry of Health and Welfare of Japan. Tokyo, 1983; pp. 3-41.
8. Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian. Chest 1990; 98: 515-516.
9. Randhawa P, Hoagland MH, Yousern SA. Diffuse pan-bronchiolitis in North America. Report of three cases and of the literature. Am J Surg Pathol 1991; 15: 43-47.
10. Homer RJ, Khoo L, Smith Gj. Diffuse panbronchiolitis in a Hispanic man with travel history to Japan. Chest 1995; 107: 1176-1178.
11. Fitzgerald JE, King TE Jr, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996; 154: 497-503.
12. Brugiere 0, Milleron B, Antoine M, Carette MF, Philippe C, Mayaud C. Diffuse panbronchiolitis in an Asian immigrant. Thorax 1996; 51: 1065-1067.
13. Zompatori M, Poletti V. Diffuse panbronchiolitis. An Italian experience. Radiol Med (Torino) 1997; 94: 680-682.
14. Fisher MS Jr, Rush VVL, Rosado-de-Christenson ML, et al. Diffuse panbronchiolitis: histologic diagnosis in unsuspected cases involving North American residents of Asian descent. Arch Pathol Lab Med 1998; 122: 156-160.
15. Schulte W, Szrepka A, Bauer PC, Guzman J, Costabel U. Diffuse panbronchiolitis. A rare differential diagnosis of chronic obstructive lung disease. Dtsch Med Wochenschr 1999; 124: 584-588.
16. Gulhan M, Erturk A, Kurt B, et al. Diffuse panbronchiolitis observed in a white man in Turkey. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 292-296.
17. Claxton S, Markos J. A case of diffuse panbronchiolitis. Aust N Z J Med 2000; 30: 99-100.
18. Martinez JA, Guimaraes SM, Ferreira RG, Pereira CA. Diffuse panbronchiolitis in Latin America. Am J Med Sci 2000; 319: 183-185.
19. Souza R, Kairalla RA, Santos U de P, Takagaki TY, Capelozzi VL, Carvalho CR. Diffuse panbronchiolitis: an underdiagnosed disease? Study of 4 cases in Brazil. Rev Hosp Clin Fac Med Sao Paulo 2002; 57: 167-174.
20. Sandrini A, Balter MS, Chapman KR. Diffuse panbronchiolitis in a Caucasian man in Canada. Can Respir J 2003; 10: 449-451.
21. Aslan AT, Ozcelik U, Talim B, et al. Childhood diffuse panbronchiolitis: a case report. Pediatr Pulmonol 2005; 40: 354-357.
22. Poletti V, Chilosi M, Trisolini R, et al. Idiopathic bronchiolitis mimicking diffuse panbronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 62-68.
23. Tomlinson IPM, Bodmer WF. The HLA system and the analysis of multifactorial genetic disease. Trends Genet 1995; 11: 493-498.
24. Sugiyama Y, Kudoh S, Maeda H, Suzaki H, Takaku F. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1990; 141: 1459-1462.
25. Imanishi T, Akaza T, Kimura A, Tokunaga. K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T, eds. HLA 1991. Vol. 1. New York, Oxford University Press, 1992; pp. 1065-1220.
26. Keicho N, Tokunaga K, Nakata K, et al. Contribution of HLA genes to genetic predisposition in diffuse panbronchiolitis. Am J Respir Crit Care Med 1998; 158: 846-850.
27. Park MH, Kim YW, Yoon HI, et al. Association of HLA class I antigens with diffuse panbronchiolitis in Korean patients. Am J Respir Crit Care Med 1999; 159: 526-529.
28. Keicho N, Ohashi J, Tamiya G, et al. Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis. Am J Hum Genet 2000; 66: 501-507.
29. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49: 531-532.
30. Akai S, Okayama H, Shimura S, Tanno Y, Sasaki H, Takishima T. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan. Am Rev Respir Dis 1992; 146: 781-783.
31. Yoshimura K, Iizuka S, Anzai C, et al. Diffuse panbronchiolitis is closely associated with mutations of the CFTR gene. Am J Respir Crit Care Med 2000; 161: A77.
32. Azuma A, Keicho N, Furukawa H, Yabe T, Kudoh S. Prolonged survival of a bare lymphocyte syndrome type I patient with diffuse panbronchiolitis treated with erythromycin. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 312-313.
33. Sugiyama Y, Kudoh S, Kitamura S. A case of the bare lymphocyte syndrome with clinical manifestations of diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1989; 27: 980-983.
34. Furukawa H, Murata S, Yabe T, et al. Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. J Clin Invest 1999; 103: 755-758.
35. Raghavan M. Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome. J Clin Invest 1999; 103: 595-596.
36. Kadota J, Mukae H, Fujii T, Seki M, Tomono K, Kohno S. Clinical similarities and differences between human T-cell lymphotropic virus type 1-associated bronchiolitis and diffuse panbronchiolitis. Chest 2004; 125: 1239-1247.
37. Homma S, Kawabata M, Kishi K, et al. Diffuse panbronchiolitis in rheumatoid arthritis. Eur Respir J 1998; 12: 444-452.
38. Homma S, Sakamoto S, Kawabata M, et al. Comparative clinicopathology of obliterative bronchiolitis and diffuse panbronchiolitis. Respiration 2006; 73: 481-487.
39. Sakito O, Kadota J, Kohno S, et al. Interleukin 1β, tumor necrosis factor-α, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42-48.
40. Oishi K, Sonoda F, Kobayashi S, et al. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun 1994; 62: 4145-4152.
41. Mukae H, Kadota J, Kohno S, et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiotitis. Am J Respir Crit Care Med 1995; 152: 613-618.
42. Hiratsuka T, Mukae H, Iiboshi H, et al. Increased concentrations of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003; 58: 425-430.
43. Ichikawa Y, Koga H, Tanaka M, Nakamura M, Tokunaga N, Kaji M. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis. Chest 1990; 98: 917-923.
44. Ninomiya H, Ichikawa Y, Koga H, Yano T, Oizumi K. Elastase activity in bronchoalveolar lavage fluid from patients with diffuse panbronchiolitis. Kansenshogaku Zasshi 1991; 65: 672-680.
45. Ichikawa Y, Ninomiya H, Koga H, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992; 146: 196-203.
46. Oda H, Kadota J, Kohno S, Hara K. Erythromycin inhibits neutrophil chernotaxis in bronchoalveoli of diffuse panbronchiolitis. Chest 1994; 106: 1116-1123.
47. Katoh S, Matsubara Y, Taniguchi H, et al. Characterization of CD44 expressed on alveolar macrophages in patients with diffuse panbronchiolitis. Clin Exp Immunol 2001; 126: 545-550.
48. Mukae H, Kadota J, Ashitani J, et al. Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis. Chest 1997; 112: 1615-1621.
49. Nishimaki K, Nawata J, Okada S, Hattori T, Ohno I. Neutrophil survival-enhancing activity in sputum from patients with diffuse panbronchiolitis. Respir Med 2005; 99: 910-917.
50. Kamio K, Matsushita I, Hijikata M, et al. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis. Am J Respir Crit Care Med 2005; 171: 949-957.
51. Kim JH, Jung K, Han JH, et al. Relation of epidermal growth factor receptor expression to mucus hypersecretion in diffuse panbronchiolitis. Chest 2004; 126: 888-895.
52. Sato A, Chida K, Iwata M, Hayakawa H. Study of bronchus-associated lymphoid tissue in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1992; 146: 473-478.
53. Fujii T, Kadota J, Mukae H, Kawakami K, Iida K, Kohno S. Gamma-delta T cells in BAL fluid of chronic lower respiratory tract infection. Chest 1997; 111: 1697-1701.
54. Mukae H, Kadota J, Kohno S, et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152: 613-618.
55. Kawakami K, Kadota J, Iida K, et al. Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis; the importance of cytotoxic T cells. Clin Exp Immunol 1997; 107: 410-416.
56. Todate A, Chida K, Suda T, et al. Increased numbers of dendritic cells in the bronchiolar tissues of diffuse panbronchiolitis. Am J Respir Crit Care Med 2000; 162: 148-153.
57. Iwata M, Colby TV, Kitaichi M. Diffuse panbronchiolitis: diagnosis and distinction from various pulmonary diseases with centrilobular interstitial foam cell accumulations. Hum Pathol 1994; 25: 357-363.
58. Kramer BW, Jobe AH, Ikegami M. Exogenous surfactant changes the phenotype of alveolar macrophages in mice. Am J Physiol Lung Cell Mol Physiol 2001; 280: L689-L694.
59. Akira M, Kitatani F, Lee YS, et al. Diffuse panbronchiolitis: evaluation with high-resolution CT. Radiology 1988; 168: 433-438.
60. Zompatori M, Poletti V, Rimondi MR, Battaglia M, Carvelli P, Maraldi F. Imaging of small airways disease, with emphasis on high resolution computed tomography. Monaldi Arch Chest Dis 1997; 52: 242-248.
61. Desai SJ, Gephartd GN, Stoller JK. Diffuse panbronchiolitis preceding ulcerative colitis. Chest 1989; 95: 1342-1344.
62. Poletti V, Zompatori M, Cancellieri A. Clinical spectrum of adult chronic bronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 183-196.
63. Nicholson AG, Colby TV, Wells AU. Histopathological approach to patterns of interstitial pneumonia in patient with connective tissue disorders. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 10-17.
64. Mukae H, Hirota M, Kohno S, et al. Elevation of tumor-associated carbohydrate antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 148: 744-751.
65. Nakano H, Ide H, Imada M, et al. Reduced nasal nitric oxide in diffuse panbronchiolitis. Am J Respir Crit Care Med 2000; 162: 2218-2220.
66. Koyama H, Nishimura K, Mio T, Ikeda A, Sugiura N, Izumi T. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease I and diffuse panbronchiolitis. Thorax 1994; 49: 540-544.
67. Nakata K. Revision of clinical guidelines for diffuse panbronchiolitis, Annual report on the study of diffuse lung disease in 1998. Grant-in Aid from the Ministry of Health and Welfare of Japan. Tokyo, 1999; pp. 109-111.
68. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998;157:1829-1832.
69. Tanimoto H. A review of the recent progress of patients with diffuse panbronchiolitis associated with Pseudomonas aeruginosa infection in Japan. Antibiot Chemother 1991; 44: 94-98.
70. Sawaki M, Mikami R, Mikasa K, Kunimatsu M, Ito S, Narita N. The long term chemotherapy with erythromycin in chronic lower respiratory tract infections-second report: including cases with Pseudomonas infections. Kansenshogaku Zasshi 1986; 60: 45-50.
71. Yamamoto M. A double-blind placebo-controlled study on the therapeutic effect of erythromycin on DPB. Annual Report on the study of diffuse lung disease in 1990. Grantin Aid from the Ministry of Health and Welfare of Japan. Tokyo, 1991; pp. 18-20.
72. Nagai H, Shishido H, Yoneda R, Yamagichi E, Tamura A, Kurashima A. Long-term low dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58: 145-149.
73. Fujii T, Kadota J, Kawakami K, et al. Long-term effect of, erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50: 1246-1252.
74. Tsang KWT. Diffuse panbronchiolits: diagnosis and treatment. Clin Pulm Med 2000; 7: 245-252.
75. Baz MA, Kussin PS, Van Trigt P, Davis RD, Roggli VL, Tapson VF. Recurrence of diffuse panbronchiolitis after lung transplantation. Am J Respir Crit Care Med 1995; 151: 895-898.
76. Kadota J, Mukae H, Tomono K, Kohno S, Nasu M. Efficacy of long-term macrolide antibiotic therapy in patients with diffuse panbronchiolitis: comparison between HLA-B54-positive and -negative cases. Int J Antimicrob Agents 2004; 24: 550-554.
77. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001; 31: 464-473.
78. Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001; 205: 1-7.
79. Oda H, Kadota J, Kohno S, Hara K. Leukotriene B4 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Chest 1995; 108: 116-122.
80. Hiratsuka T, Mukae H, Iiboshi H, et al. Increased concentrations of human β-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003; 58: 425-430.
81. Sakito O, Kadota J, Kohno S, et al. Interleukin 1β, tumor necrosis factor-α, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63: 42-48.
82. Ichikawa Y, Koga H, Tanaka M, Nakamura M, Tokunaga N, Kaji M. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis. Chest 1990; 98: 917-923.
83. Ichikawa Y, Ninomiya H, Koga H, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992; 146: 196-203.
84. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117: Suppl 9A, 5S-11S.
85. Shimizu T, Shimizu S, Hattori R, Gabazza EC, Majima Y. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003; 168: 581-587.
86. Kaneko Y, Yanagihara K, Seki M, et al. Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am J Physiol Lung Cell Mol Physiol 2003; 285: L847-L853.
87. Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992; 5: 234-238.
88. Nakamura H, Fujishima S, Inoue T, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J 1999; 13: 1371-1379.
89. Mikasa K, Sawaki M, Kita E, et al. Long-term chemotherapy using erythromycin (EM) for chronic lower airway infection: effectiveness of clarithromycin in EM ineffective cases - the fourth report. Kansenshogaku Zasshi 1992; 66: 1097-1104.
90. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39: 1688-1690.
91. Shirai T, Sato A, Chida K. Effect of 14-membered ring macrolide therapy on chronic respiratory tract infections and polymorphonuclear leukocyte activity. Intern Med 1995; 34: 469-474.
92. Kudoh S. Applying lessons learned in the treatment of diffuse panbronchiolitis to other chronic inflammatory diseases. Am J Med 2004; 117: Suppl. 9A, 12S-19S.
93. Kadota J, Mukae H, Mizunoe S, et al. Long-term macrolide antibiotic therapy in the treatment of chronic small airway disease clinically mimicking diffuse panbronchiolitis. Intern Med 2005; 44: 200-206.